Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

NCT01193595 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Malignant

Interventions

DRUG: Ombrabulin (AVE8062)
DRUG: bevacizumab

Sponsor

Sanofi